117 related articles for article (PubMed ID: 27748897)
1. SCCOHT tumors acquire chemoresistance and protection by interacting mesenchymal stroma/stem cells within the tumor microenvironment.
Otte A; Yang Y; von der Ohe J; Melzer C; Hillemanns P; Feuerhake F; Hass R
Int J Oncol; 2016 Dec; 49(6):2453-2463. PubMed ID: 27748897
[TBL] [Abstract][Full Text] [Related]
2. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
[TBL] [Abstract][Full Text] [Related]
3. Acquisition of new tumor cell properties by MSC-derived exosomes.
Yang Y; Bucan V; Baehre H; von der Ohe J; Otte A; Hass R
Int J Oncol; 2015 Jul; 47(1):244-52. PubMed ID: 25963929
[TBL] [Abstract][Full Text] [Related]
4. Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
Hassan MS; Williams F; Awasthi N; Schwarz MA; Schwarz RE; Li J; von Holzen U
Sci Rep; 2019 Nov; 9(1):17608. PubMed ID: 31772236
[TBL] [Abstract][Full Text] [Related]
5. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
Chen HM; Tsai CH; Hung WC
Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
[TBL] [Abstract][Full Text] [Related]
6. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
Zillhardt M; Park SM; Romero IL; Sawada K; Montag A; Krausz T; Yamada SD; Peter ME; Lengyel E
Clin Cancer Res; 2011 Jun; 17(12):4042-51. PubMed ID: 21551255
[TBL] [Abstract][Full Text] [Related]
7. A tumor-derived population (SCCOHT-1) as cellular model for a small cell ovarian carcinoma of the hypercalcemic type.
Otte A; Göhring G; Steinemann D; Schlegelberger B; Groos S; Länger F; Kreipe HH; Schambach A; Neumann T; Hillemanns P; Park-Simon TW; Hass R
Int J Oncol; 2012 Aug; 41(2):765-75. PubMed ID: 22581215
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.
Wilson AJ; Lalani AS; Wass E; Saskowski J; Khabele D
Gynecol Oncol; 2012 Dec; 127(3):579-86. PubMed ID: 23010348
[TBL] [Abstract][Full Text] [Related]
9. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Huynh H; Ong R; Soo KC
Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stem cells directly interact with breast cancer cells and promote tumor cell growth in vitro and in vivo.
Mandel K; Yang Y; Schambach A; Glage S; Otte A; Hass R
Stem Cells Dev; 2013 Dec; 22(23):3114-27. PubMed ID: 23895436
[TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228.
Pluchino LA; Choudhary S; Wang HC
Cancer Lett; 2016 Oct; 381(1):124-32. PubMed ID: 27477899
[TBL] [Abstract][Full Text] [Related]
12. Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models.
Grojean M; Schwarz MA; Schwarz JR; Hassan S; von Holzen U; Zhang C; Schwarz RE; Awasthi N
J Cell Mol Med; 2021 Jun; 25(11):4950-4961. PubMed ID: 33939252
[TBL] [Abstract][Full Text] [Related]
13. Human mesenchymal stroma/stem cells exchange membrane proteins and alter functionality during interaction with different tumor cell lines.
Yang Y; Otte A; Hass R
Stem Cells Dev; 2015 May; 24(10):1205-22. PubMed ID: 25525832
[TBL] [Abstract][Full Text] [Related]
14. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
Xiao JJ; Huang Y; Dai Z; Sadée W; Chen J; Liu S; Marcucci G; Byrd J; Covey JM; Wright J; Grever M; Chan KK
J Pharmacol Exp Ther; 2005 Jul; 314(1):467-75. PubMed ID: 15833893
[TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of cancer cell death and reduction of clonogenic resistance by cisplatin and FK228.
Choudhary S; Sood S; Wang HC
Biochem Biophys Res Commun; 2013 Jun; 436(2):325-30. PubMed ID: 23743194
[TBL] [Abstract][Full Text] [Related]
16. [Inhibitory effect of a novel histone deacetylases inhibitor FK228 on human colon cancer HCT-116 cells in vitro and in vivo].
Xu DB; Wang YL; Yue Y; Wu SC; Ding H
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):814-8. PubMed ID: 24447477
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Adachi M; Zhang Y; Zhao X; Minami T; Kawamura R; Hinoda Y; Imai K
Clin Cancer Res; 2004 Jun; 10(11):3853-62. PubMed ID: 15173094
[TBL] [Abstract][Full Text] [Related]
19. Depsipeptide (FK228) inhibits growth of human prostate cancer cells.
Lai MT; Yang CC; Lin TY; Tsai FJ; Chen WC
Urol Oncol; 2008; 26(2):182-9. PubMed ID: 18312939
[TBL] [Abstract][Full Text] [Related]
20. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
